NNVC NanoViricides Inc
Company Analysis
Latest News
🟢 NanoViricides is trading 5.2% up today on no clear company-specific news or catalysts
NanoViricides is trading at $1.63 (+5.16%) in after-hours trading with no company-specific announcements, earnings releases, or late-breaking news found to...
🔴 NanoViricides is trading 5.3% down today amid broader biotech weakness and risk-off sentiment
NanoViricides is trading at $1.52 (-5.28%) as the stock faces downward pressure in the absence of company-specific catalysts. • The decline appears consistent...
NanoViricides Funds Phase II Ebola Trial, Advancing Oral Gummy Treatment
NanoViricides secured financing for a Phase II clinical trial of its oral Ebola drug, NV-387. The company is awaiting regulatory approval from ACOREP to begin...
🟢 NanoViricides is trading 5.8% up today on momentum follow-through despite no fresh news
NanoViricides is trading 5.8% up today at $1.63 on momentum follow-through and high-volatility trading, despite a lack of fresh company-specific news. • No...
🟢 NanoViricides Inc is trading 8.11% up
NNVC is trading at $1.60, up 8.11%.
NanoViricides Secures $3.8 Million in Registered Direct Offering
NanoViricides, Inc. entered a securities purchase agreement with a single institutional investor on July 24, 2026. The registered direct offering expects to...
🟢 NanoViricides is trading 5.2% up today, rebounding from an earlier drop with no clear catalyst identified
NanoViricides is trading at $1.56 (5.2% up) in after-hours trading, rebounding from a 10.5% drop earlier on July 24 to $1.37 with no clear news catalyst. *...
🔴 NanoViricides is trading 10.5% down today with no clear catalyst identified
NanoViricides is trading 10.5% lower at $1.37 following a sharp drop from its July 23 close of $1.53, despite a lack of fresh company-specific news, earnings,...
🔴 NanoViricides is trading 8.6% down today with no clear company-specific catalyst identified
NanoViricides is trading 8.59% down at $1.40 in pre-market with no clear company-specific catalyst identified after a sharp move lower from its $1.53 close on...
🔴 NanoViricides is trading 5% down today on profit-taking and biotech sector weakness
NanoViricides is trading 5% down today at $1.66 as the stock faces profit-taking following a recent rally and broader pressure on the biotechnology sector. •...
🔴 NanoViricides is trading 5.28% down today amid broader biotech weakness and risk-off pressure
NanoViricides is trading at $1.68 (-5.28%) following a sharp move lower in early trading despite a lack of company-specific news, filings, or analyst...
🟢 NanoViricides is trading 5% up today on speculative interest
NanoViricides is trading 5% up at $1.81, extending a volatile recent upswing despite a lack of fresh company-specific headlines, filings, or analyst...
🟢 NanoViricides is trading 10.0% up
NanoViricides is trading at $1.81, up 10.0% from a comparison close of $1.65 during regular trading. This is a price-action follow-up, so a separate catalyst...
🟢 NanoViricides is trading 5.2% up today, extending a multi-day rally despite a weak biotech tape
NanoViricides is trading 5.2% up at $1.74 today, extending a strong multi-day rally that began earlier in July while moving independently of a broader decline...
🟢 NanoViricides is trading 11.1% up
NanoViricides is trading at $1.68, up 11.1% from a comparison close of $1.51 during regular trading. This is a price-action follow-up, so a separate catalyst...
🟢 NanoViricides soars 6% on Ebola trial approval in DRC and bullish Noble Capital coverage
NanoViricides is trading at $1.60 (+5.96%), gaining momentum after receiving approval for a Phase II Ebola trial and continued positive sentiment from analyst...
🔴 NanoViricides is trading 5.2% down today on profit-taking following a sharp multi-day rally
NanoViricides is trading 5.2% down today at $1.53 as the stock undergoes consolidation following a significant multi-day run. • The recent momentum was fueled...
🟢 NanoViricides is trading 5.4% up today on Outperform rating and NV-387 clinical progress
NanoViricides is trading at $1.63 (up 5.4%), extending yesterday’s jump after Noble Capital Markets initiated coverage on the stock with an Outperform rating...
🟢 NNVC is trading 6% up today on "Outperform" analyst rating and NV-387 clinical progress
NanoViricides (NNVC) is trading at $1.55 (up 6%) after Noble Capital Markets initiated coverage with an "Outperform" rating and a $6.00 price target. The...
NanoViricides advances oral Ebola drug to Phase II, targeting DRC outbreak
NanoViricides, Inc. announced on July 6, 2026, that it is advancing its broad-spectrum antiviral drug, NV-387, toward a Phase II clinical trial in the...